Compare Stocks: ATYR, WHWK, PLX, and NBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.53 +6.7%	$0.51	$0.40 ▼ $6.50	$51.48M	0.54	2.02 million shs	739,831 shs
NBP I-Mab	$1.65 +2.2%	$1.74	$1.46 ▼ $6.79	$190.24M	1.47	792,425 shs	202,481 shs
PLX Protalix BioTherapeutics	$2.38 +2.4%	$2.22	$1.41 ▼ $3.19	$191.36M	N/A	945,424 shs	540,766 shs
WHWK Whitehawk Therapeutics	$4.17 +5.2%	$4.14	$1.57 ▼ $5.49	$205.82M	0.77	312,425 shs	343,292 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+1.30%	+0.49%	-16.96%	-41.58%	-89.53%
NBP I-Mab	+0.63%	-9.55%	-24.77%	-32.35%	+160,999,900.00%
PLX Protalix BioTherapeutics	-2.11%	-3.33%	0.00%	+18.37%	+60.00%
WHWK Whitehawk Therapeutics	+2.86%	+7.03%	-5.49%	-5.94%	+127.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.53 +6.7%	$0.51	$0.40 ▼ $6.50	$51.48M	0.54	2.02 million shs	739,831 shs
NBP I-Mab	$1.65 +2.2%	$1.74	$1.46 ▼ $6.79	$190.24M	1.47	792,425 shs	202,481 shs
PLX Protalix BioTherapeutics	$2.38 +2.4%	$2.22	$1.41 ▼ $3.19	$191.36M	N/A	945,424 shs	540,766 shs
WHWK Whitehawk Therapeutics	$4.17 +5.2%	$4.14	$1.57 ▼ $5.49	$205.82M	0.77	312,425 shs	343,292 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+1.30%	+0.49%	-16.96%	-41.58%	-89.53%
NBP I-Mab	+0.63%	-9.55%	-24.77%	-32.35%	+160,999,900.00%
PLX Protalix BioTherapeutics	-2.11%	-3.33%	0.00%	+18.37%	+60.00%
WHWK Whitehawk Therapeutics	+2.86%	+7.03%	-5.49%	-5.94%	+127.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.25	Hold	$17.00	3,138.10% Upside
NBP I-Mab	2.00	Hold	$9.00	447.11% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	405.26% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	96.88% Upside

Current Analyst Ratings Breakdown

Latest ATYR, WHWK, PLX, and NBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
6/26/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	WHWK Whitehawk Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/5/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/1/2026	NBP I-Mab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/20/2026	ATYR aTyr Pharma	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/18/2026	NBP I-Mab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/8/2026	WHWK Whitehawk Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	270.93	N/A	N/A	$0.69 per share	0.76
NBP I-Mab	$3.89M	48.91	N/A	N/A	$2.00 per share	0.82
PLX Protalix BioTherapeutics	$76.38M	2.51	$0.13 per share	17.80	$0.47 per share	5.05
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.73	N/A	N/A	N/A	N/A	-100.14%	-73.55%	8/6/2026 (Estimated)
NBP I-Mab	-$46.27M	-$0.36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.18	N/A	7.66	N/A	-21.03%	-30.89%	-11.74%	N/A
WHWK Whitehawk Therapeutics	-$20.60M	-$1.68	N/A	N/A	N/A	N/A	-79.63%	-74.01%	N/A

Latest ATYR, WHWK, PLX, and NBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ATYR aTyr Pharma	-$0.15	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	ATYR aTyr Pharma	-$0.16	-$0.11	+$0.05	-$0.11	N/A	N/A
5/7/2026	Q1 2026	WHWK Whitehawk Therapeutics	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
NBP I-Mab	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.78	5.78
NBP I-Mab	N/A	8.09	8.09
PLX Protalix BioTherapeutics	N/A	1.98	1.27
WHWK Whitehawk Therapeutics	N/A	11.36	11.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
NBP I-Mab	38.38%
PLX Protalix BioTherapeutics	16.53%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
NBP I-Mab	22.10%
PLX Protalix BioTherapeutics	6.70%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.05 million	92.41 million	Optionable
NBP I-Mab	380	115.65 million	90.09 million	N/A
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable
WHWK Whitehawk Therapeutics	21	49.45 million	24.78 million	N/A

ATYR, WHWK, PLX, and NBP Headlines

Recent News About These Companies

Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

July 30, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 30, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts

July 25, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest

July 14, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners

July 13, 2026 | marketbeat.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 15, 2026 | prnewswire.com

Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know

May 14, 2026 | theglobeandmail.com

Whitehawk Therapeutics secures $87.5M PIPE financing

May 14, 2026 | seekingalpha.com

Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing

May 13, 2026 | prnewswire.com

Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026 | finanznachrichten.de

Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATYR, WHWK, PLX, and NBP Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.52 +0.03 (+6.71%)

As of 03:37 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

I-Mab NASDAQ:NBP

$1.64 +0.04 (+2.17%)

As of 03:37 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Protalix BioTherapeutics NYSE:PLX

$2.38 +0.06 (+2.37%)

As of 03:37 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Whitehawk Therapeutics NASDAQ:WHWK

$4.16 +0.21 (+5.18%)

As of 03:38 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, WHWK, PLX, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, WHWK, PLX, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, WHWK, PLX, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATYR, WHWK, PLX, and NBP Company Descriptions

aTyr Pharma NASDAQ:ATYR

I-Mab NASDAQ:NBP

Protalix BioTherapeutics NYSE:PLX

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATYR, WHWK, PLX, and NBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATYR, WHWK, PLX, and NBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATYR, WHWK, PLX, and NBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATYR, WHWK, PLX, and NBP Company Descriptions

aTyr Pharma NASDAQ:ATYR

I-Mab NASDAQ:NBP

Protalix BioTherapeutics NYSE:PLX

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools